LDS/Medical Tests/CDKN1C Gene Mutation Analysis

CDKN1C Gene Mutation Analysis

Located on chromosome number 11, the CDKN1C gene codes for a protein- p57(KIP2), which in turn inhibits various G1 cyclin/Cdk system. It also down regulates cell proliferation. The CDKN1C gene shows preferential maternal expression and paternal allele generally remains unexpressed. Absence of CDKN1C expression resulting from mutations of the maternally inherited allele is postulated to contribute to the clinical phenotype. CDKN1C gene mutations are implicated in several disorders including Beckwith-Wiedemann syndrome (BWS), Silver-Russell syndrome (SRS), IMAGE syndrome (Intrauterine growth retardation, Metaphyseal dysplasia, Adrenal hypoplasia congenita, Genital anomalies) and IMAGEI syndrome (Intrauterine growth retardation, Metaphyseal dysplasia, Adrenal hypoplasia congenita, Genital anomalies, Immunodeficiency).

Children affected with BWS show abnormally large bodies, abnormally large tongues, abnormalities of the abdominal wall, ears, and kidneys, predisposition for pediatric tumors and hypoglycemia in the newborn period. Mothers carrying fetuses with BWS may have pregnancy complications such as premature delivery, polyhydramnios, large placenta and long umbilical cord.

CDKN1C also functions as a tumor suppressor gene and children with BWS are at risk for Wilms tumor, adrenocortical carcinoma, neuroblastoma, and rhabdomyosarcoma.

Children affected with “IMAGE syndrome” show features of intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies. Genital abnormalities like hypospadias, cryptorchidism, hypogonadotropic hypogonadism and micropenis, are common in male offspring. Other features include depressed nasal bridge, frontal bossing, and hydronephrosis.

  • Diagnosis of inherited disorders such as Beckwith-Wiedemann syndrome, Silver-Russell syndrome and IMAGE syndrome
  • As a screening test for preimplantation genetic disorders prior to In-vitro fertilization, so that the embryos carrying mutations are excluded from implantation
Any alteration known as pathogenic mutation will be consistent with a diagnosis of Beckwith-Wiedemann syndrome. Parental testing may be helpful in clarifying the origin of the identified mutation and differentiating between an inherited and de novo event First-line testing is directed at methylation abnormalities in the target regions. This test provides molecular diagnosis of BWSP with loss or gain of methylation at the target site. Negative results decrease the likelihood but does not rule out the diagnosis of Beckwith-Wiedemann syndrome

No reportable variants were identified

Real-Time PCR for targeted mutations, Conventional Sequencing, Next Generation Sequencing (NGS).

Whole blood (EDTA). 

Stability

  • Room: 3-5 days
  • Refrigerated: 7-14 days

Other samples like buccal swabs, fibroblasts, mesenchymal cells from surgical excisions can also be used.

Rare defects can be evaluated using cytogenetic analysis and fluorescent in situ hybridization (FISH) of the target region.
7-14 Days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login